Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Essilor International    EI   FR0000121667

News SummaryMost relevantAll newsSector newsTweets

ESSILOR INTL. : Essilor Continues to Expand in the United States

share with twitter share with LinkedIn share with facebook
share via e-mail
01/31/2013 | 06:35am CEST

Regulatory News:

Essilor (Paris:EI) is continuing to strengthen its positions in the United States, the world's leading market for ophthalmic lenses, with the acquisition of a lens manufacturer and a new prescription laboratory.

The Company has announced the acquisition of an 80% share in X-Cel Optical, a manufacturer of ophthalmic lenses based in Minnesota (US). Leveraging its widely recognized, high performance technical expertise, X-Cel Optical offers a wide range of niche products, the vast majority of which are bi- and tri-focal, stock and variable-tint lenses. The line-ups are produced in various materials, including Trivex?. With a refraction index of 1.53 and impact resistance comparable to that of polycarbonate, Trivex? is enjoying rapid sales growth.

X-Cel Optical produces just over two million lenses a year and generates full-year revenue of approximately $33 million.

The development of the X-Cel Optical product line, which fits very well with Essilor's, will be led by the Group's various distribution networks in the United States, comprising both proprietary and independent laboratories, and around the world. The X-Cel Optical offer may also be moved upmarket, using Essilor's leading-edge technologies, in particular the Crizal® range of surface coatings, as a lever.

In addition, the partnership will enable Essilor to optimize its sourcing strategy. Lastly, Essilor and X-Cel Optical may also share their engineering skills and capabilities to optimize their production processes.

Essilor is also continuing to deepen its local distribution network in the United States to capture the market's growth potential for value-added lenses. The Company has signed a partnership with Lenstech Optical, a prescription laboratory in Indiana that generates annual revenue of $6 million.

In the future, Essilor will activate the usual value-creation levers by providing Lenstech Optical with new technologies that will speed the distribution of its flagship brands, including Varilux® and Crizal®, in the partner's catchment area.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around ?150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog? and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of ?4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and
Financial Communication
Véronique Gillet ? Sébastien Leroy ? Ariel Bauer
Phone: +33 (0)1 49 77 42 16
Media Relations
Maïlis Thiercelin
Phone: +33 (0)1 49 77 45 02

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
10/23DJLUXOTTICA : 3Q Sales Fall; Backs Guidance for 2017
10/20 ESSILOR INTERNATIONAL : Laura viscovich appointed vice president corporate commu..
10/19 ESSILOR INTERNATIONAL : Patent Application Titled "Machining Method by Turning a..
10/16 ESSILOR INTERNATIONAL : New achievement towards the combination of essilor and l..
10/12 ESSILOR INTERNATIONAL : Patent Issued for Composition for Transparent Antistatic..
10/12 ESSILOR INTERNATIONAL : Launches campaign putvisionfirst to raise awareness abou..
10/12 NEWS RELEASE : New achievement towards the combination of Essilor and Luxottica ..
10/12 NEWS RELEASE : New achievement towards the combination of Essilor and Luxottica ..
10/10 ESSILOR INTERNATIONAL : Hilary halper appointed cfo at essilor
10/09 ESSILOR INTERNATIONAL : Graldine Picaud Appointed Group CFO at LafargeHolcim
More news
News from SeekingAlpha
09/26 EU launches full investigation into Essilor-Luxottica merger
09/11 EU regulators to review Luxottica-Essilor merger
08/03 Lack Of Takeovers Sees Medtech Hiring Staff Again
07/28 Essilor International's (ESLOF) on Q2 2017 Results - Earnings Call Transcript
07/28 Essilor International SA reports 1H results
Financials (€)
Sales 2017 7 532 M
EBIT 2017 1 331 M
Net income 2017 848 M
Debt 2017 1 861 M
Yield 2017 1,49%
P/E ratio 2017 26,60
P/E ratio 2018 23,63
EV / Sales 2017 3,18x
EV / Sales 2018 2,99x
Capitalization 22 072 M
Duration : Period :
Essilor International Technical Analysis Chart | EI | FR0000121667 | 4-Traders
Technical analysis trends ESSILOR INTERNATIONAL
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 121 €
Spread / Average Target 20%
EPS Revisions
Hubert Sagnières Chairman & Chief Executive Officer
Laurent Vacherot President, Co-Chief Operating Officer & Director
Paul du Saillant Co-Chief Operating Officer
Jean Carrier-Guillomet Co-Chief Operating Officer
Hilary Halper Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
INTEROJO CO. LTD.--.--%352